KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Abbott Laboratories (ABT) Cost of Revenue (2016 - 2025)

Abbott Laboratories' Cost of Revenue history spans 17 years, with the latest figure at $4.9 billion for Q4 2025.

  • For Q4 2025, Cost of Revenue changed 0.4% year-over-year to $4.9 billion; the TTM value through Dec 2025 reached $19.3 billion, up 3.28%, while the annual FY2025 figure was $19.3 billion, 3.28% up from the prior year.
  • Cost of Revenue for Q4 2025 was $4.9 billion at Abbott Laboratories, down from $5.1 billion in the prior quarter.
  • Across five years, Cost of Revenue topped out at $5.1 billion in Q3 2025 and bottomed at $4.3 billion in Q1 2023.
  • The 5-year median for Cost of Revenue is $4.6 billion (2022), against an average of $4.7 billion.
  • The largest annual shift saw Cost of Revenue skyrocketed 51.61% in 2021 before it decreased 13.15% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $4.8 billion in 2021, then dropped by 3.63% to $4.6 billion in 2022, then dropped by 0.81% to $4.6 billion in 2023, then grew by 8.47% to $4.9 billion in 2024, then decreased by 0.4% to $4.9 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Cost of Revenue are $4.9 billion (Q4 2025), $5.1 billion (Q3 2025), and $4.9 billion (Q2 2025).